Skip to content

JBIO JBIO PP&E (Net)

PP&E (Net) at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$3.63M-25.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$1.28M-26.5%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$342K-43.7%
Vor Biopharma logo
Vor BiopharmaVOR
$565K-90.6%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.13M-2.8%
Annexon logo
AnnexonANNX
$10.11M-17.1%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's PP&E (net)?
JBIO (JBIO) reported PP&E (net) of $157K in Q1 2026.
How has JBIO's PP&E (net) changed year-over-year?
JBIO's PP&E (net) increased by 7750.0% year-over-year, from $2K to $157K.
What is the long-term trend for JBIO's PP&E (net)?
Over 5 years (2020 to 2025), JBIO's PP&E (net) has grown at a 34.2% compound annual growth rate (CAGR), from $39K to $170K.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.